Sotagliflozin, an inhibitor of sodium–glucose cotransporters 1 and 2 (SGLT1/2), as a new therapeutic approach for patients with type 1 diabetes mellitus

Mirella Czapska, Kamila Babkiewicz, Szczepan Pabis, Katarzyna Skórzyńska-Dziduszko


Sotagliflozin (SOTA) is a dual inhibitor of SGLT1 and SGLT2 used in adults with type 1 diabetes. The mechanism of action, based on the inhibition of both the SGLT1 and SGLT2 cotransporters, allows simultaneous increase of glucose excretion and slowing down the absorption of glucose in the intestine. Recently, test results have been published showing a beneficial effect of sotagliflozin on type 1 diabetes control [1,2,3].
Sotagliflozin use leads to a significant reduction in glycosylated haemoglobin (HbA1c) [1,2,3] , postprandial glucose reduction [1,2,3], weight loss [1,2,3],  systolic blood pressure reduction  [1,2,3] and reducing the risk of hypoglycaemia during the treatment [1,2,3].
Treatment of type 1 diabetes is based on a model of intensive, functional insulin therapy with the use of human insulin preparations or analogues of this insulin [10]. The therapy is carried out by multiple, subcutaneous injections of insulin doses or in the form of continuous insulin infusion with a personal insulin pump [10].
According to the recommendations of the Polish Diabetes Association (PTD) for patients with type 1 diabetes in terms of glycemic control, the primary goal is to maintain HbA1C  7% (53mmol / mol) and when the goal is not associated with the risk of hypoglycaemia, the target value is  6.5%. The use of proper treatment and sustaining HbA1C at the level recommended by PTD allows to prevent acute and chronic complications of the disease and at the same time allows patients to live actively and, consequently, improves their life quality [10].
According to recently published studies, preparations from SGLT-1 and SGLT-2 inhibitor groups may be helpful in obtaining and sustaining the treatment objective recommended by PTD.


SGLT1 and SGLT2 inhibitor; sotagliflozin; type 1 diabetes (T1D); HbA1C; hypoglycemia

Full Text:



SK Garg.Henry RR.Banks al. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes. N Engl J Med.2017 Dec 14; 377 (24): 2337-2348.

Danne T.Cariou B.Banks PEt al. Reductions in HbA1c and Hypoglycemia at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study. Diabetes Care.2018 Sep; 41 (9): 1981-1990.

Buse JB.SK Garg.Rosenstock Jet al. Sotagliflozin in Optimized Combination With Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. Diabetes Care.2018 Sep; 41 (9): 1970-1980.

Claire Baker, Suman Wason, Philip Banks et al. 1Diabetes Endocrine & Associates, PC, Omaha, NE; 2Lexicon Pharmaceuticals, Inc., The Woodlands, TX, USA; 3The inTandem4 Writing Group: Anna Chang, Thomas Danne, Gestures Diane Palmer et al. , A 12-Week Dose-Ranging Study of Sotagliflozin, a dual inhibitor of SGLT2 and SGLT1, as Adjunct Therapy in this Insulin Type 1 Diabetes (inTandem4, NCT02459899) European Association for the Study of Diabetes 53rdAnnual Meeting, 11-15 September 2017, Lisbon, Portugal. These data were previously presented at the American Diabetes Association 76thScientific Sessions, June 9-13, 2017, San Diego, CA.

Dandona P.Mathieu C.Phillip M. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The Depict-1 52-Week Study. Diabetes Care.2018 Dec; 41 (12): 2552-2559.

Tatoń J., A. Czech Republic: Diabetes, manual diagnosis and therapy Elamed Katowice 2009, ed. 1

Czupryniak L., Strojek K .: Diabetologia, Via Medica, Gdańsk 2018, ed. 4.

Frank E., Walicka M .: The treatment of diabetes in clinical practice, PZWL, Warsaw 2018 wyd.1.

Szymańska-Garbatsch E., L. Czupryniak, Problems in the treatment of diabetes-93 clinical cases. Disposal in accordance with the recommendations of the Polish Diabetes Association, the MP 2018 wyd.1.

Practical Diabetology: Recommendations for the clinical management of patients with diabetes in 2018, Volume 4, No.1, 2018

Otto-Buczkowska E., P. Jarosz-Chobot, Polańska J., Experimental and Clinical Diabetologia 2002 tom2, n R6.

Zambrowicz B et al.LX4211, a dual SGLT1 / SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.Clin Pharmacol Ther.2012 Aug; 92 (2): 158-69.

Powell DR, M Smith.Greer J et al. LX4211 Increases serum glucagon-like peptide 1 and peptide YY Reducing levels by sodium / glucose cotransporter 1 (SGLT1) -mediated intestinal absorption of glucose.J Pharmacol Exp Ther.2013 May; 345 (2): 250-9

Powell DR, DaCosta CM.M Smith et al. Effect of LX4211 on glucose homeostasis and body composition in preclinical models. J Pharmacol Exp Ther.2014 Aug; 350 (2): 232-42.

Zambrowicz BFreiman J.PM al.Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, a postprandial glucose, insulin, glucagon-like peptide 1, peptide tyrosine and tyrosine in a dose-timing study in healthy subjects.Clin Ther.2013 Aug; 35 (8): 1162-1173.

Mudaliar S Polidori D.Zambrowicz B et al. Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench Bedside it. Diabetes Care.2015 Dec; 38 (12): 2344-53.

AT sands, Zambrowicz BP .Rosenstock J et al. Sotagliflozin and dual SGLT1 and SGLT2 inhibitor, as Adjunct Therapy is Insulin in Type 1 Diabetes. Diabetes Care.2015 Jul; 38 (7): 1181-8.

Rieg T Masuda T.Gerasimova MEt al. Increase in SGLT1-mediated transport Explains renal glucose reabsorption during genetic and pharmacological inhibition of SGLT2 in euglycemia.Am J Physiol Renal Physiol.2014 Jan; 306 (2): F188-93.

Bakris GL, Fonseca VA.K Sharma et al. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.Kidney Int.2009 Jun; 75 (12): 1272-1277.

Henry RR, Rosenstock J.Edelman S et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care.2015 Mar; 38 (3): 412-9.

Vallon V Platt KA.Cunard R et al. SGLT2 mediates glucose reabsorption in the early proximal tubule.J Am Soc Nephrol.2011 Jan; 22 (1): 104-12.

Ferrannini E, E Muscelli.S Frascerra et al. Metabolic response is a sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.J Clin Invest.2014 Feb; 124 (2): 499-508.

Tahara A, Takasu T.Yokono M et al. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and Pharmacologic effects.J Pharmacol Sci.2016 Mar; 130 (3): 159-69.

Liang Y, Arakawa K.Ueta KEt al. Effect of canagliflozin It renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One.2012; 7 (2): e30555.

Heerspink HJ, BA Perkins.DH Fitchett et al. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Kidney and Cardiovascular Effects Potential Mechanisms, and Clinical Applications.Circulation.2016 Sep 6; 134 (10): 752-72.

Ferrannini G Hach T.S Crowe et al. After Energy Balance Sodium-Glucose Cotransporter 2 Inhibition.Diabetes Care.2015 Sep; 38 (9): 1730-5.

Kawasoe S Maruguchi Y.S Kajiya et al. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.BMC Pharmacol Toxicol.2017 Apr 10; 18 (1): 23.

C. Majewski, Bakris GL. Blood pressure reduction: an added benefit of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes. Diabetes Care.2015 Mar; 38 (3): 429-30.

Wright EM,E Turk.MG Martin. Molecular basis for glucose-galactose malabsorption.Cell Biochem Biophys.2002; 36 (2-3): 115-21.

Roder PV EC Geillinger.TS Zietek et al. The role of SGLT1 and GLUT2 in intestinal glucose transport and sensing.PLoS One.2014 Feb 26; 9 (2): e89977.

Powell DR, DaCosta CM.Gay J.Ding ZM et al. Improved glycemic control in mice lacking SGLT1 and SGLT2.Am J Physiol Endocrinol Metab.2013 Jan 15; 304 (2): E117-30.

Goodwin NC Ding ZM.Harrison BA.Strobel ED et al. Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes.J Med Chem.2017 Jan 26; 60 (2): 710-72.

Dobbins RL Greenway FL.Chen L.Liu Y et al. Selective sodium-dependent glucose transporter 1 inhibitors block impair glucose absorption and glucose-dependent insulinotropic peptide release. Am J Physiol Gastrointest Liver Physiol.2015 Jun 1; 308 (11): G946-54.

Zambrowicz B Ding ZM.And Ogbaa. et al. Effects of LX4211, a dual SGLT1 / SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes. Clin Ther.2013 Mar; 35 (3): 273-285.

Lapuerta P. Zambrowicz B.Strumph P.A Sands.Development of sotagliflozin and dual sodium-dependent glucose transporter 1/2 inhibitor. Diab Vasc Dis Res.2015 Mar; 12 (2): 101-10.

Sabino Silva-R RC Mori, David Silva-A, Okamoto MM, et al.The Na (+) / glucose cotransporters: genes from this therapy.Braz J Med Biol Res.2010 Nov; 43 (11): 1019-1026.



  • There are currently no refbacks.

Copyright (c) 2018 © The Author(s)

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

POL-index 2011 - 2014

BASE 2011 - 2014

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

Find a library that holds this journal:

Journal Language(s): English 

PBN Poland



Redaction, Publisher and Editorial Office

Instytut Kultury Fizycznej Uniwersytet Kazimierza Wielkiego w Bydgoszczy, Institute of Physical Education Kazimierz Wielki University in Bydgoszcz, Poland 85-091 Bydgoszcz ul. Sportowa 2 Copyright by Instytut Kultury Fizycznej UKW w Bydgoszczy  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at

SIC Science citation index (calculated on the basis of TCI and Page Rank) 0

Russian Impact factor 0.16

Indexed in Index Copernicus Journals Master List.,p24782242,3.html

ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

The InfoBase Index IBI Factor for the year 2015 is 3.56 in InfoBase


Universal Impact Factor 1.78 for year 2012. (

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ)

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski